

SIGNIFICANCE OF AUTOANTIBODIES IN CHILDREN WITH CHRONIC LIVER DISEASE

Protocol of Thesis

**Submitted for partial fulfillment of master degree
In PEDIATRICS**

By



Mostafa Mohammed Mohammed Sira

M.B., B.Ch.

Supervisors

53761

Prof. Dr. Tawhida Yassen Abdel Ghaffar

Assistant Professor of Pediatrics
Faculty of Medicine, Ain Shams University

Dr. Heba Hassan El-Sedfy

Lecturer of Pediatrics
Faculty of Medicine, Ain Shams University

Prof. Dr. Ahmed Abbas Raouf

Professor of Biochemistry
Faculty of Medicine & Dean of Liver Institute
Menoufiya University

**FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY
1997**



618.92352
M-M
sheds yam

(P)


Handwritten signature or initials.

Handwritten signature or initials.





بِسْمِ اللَّهِ
الرَّحْمَنِ الرَّحِيمِ



CONTENTS

Introduction	
Review of literature	
<i>Chronic liver disease</i>	
* Chronic hepatitis	
• Autoimmune hepatitis	12-22
• HBV-CAH	23-30
• HCV-CAH	31-37
• HDV-CAH	38
• Wilson's disease	39-48
• Chronic drug hepatitis	49-50
* Cirrhosis	51-58
* Schistosomiasis	59-64
* Biliary diseases	
• Primary sclerosing cholangitis	65-69
• Extrahepatic biliary atresia	70-79
* Others	
• Veno-occlusive disease (VOD)	80-81
• Glycogen storage disease (GSD)	82-87
<i>Immunological disorders in chronic liver disease</i>	88
* Disturbances of humoral immunity	91-93
* Disturbances of cellular immunity	94-95
* Non-specific immune functions	96
* Hypergammaglobulinaemia	97
* Autoantibodies	98
Subjects and Methods	110-117
Results	118-161
Discussion	162-169
Summary and Conclusion	170-172
References	173-208

ACKNOWLEDGEMENT

I like first to raise my deepest thanks and gratitude to God who helped me to accomplish this work.

I would like to express my thanks to Prof. Dr. Tawhida Yassen Abdel-Ghaffar, Assistant Professor of Pediatrics, Faculty of Medicine, Ain Shams University for her sincere help and reliable direction all over the conduction of this work.

I would like to express my deepest gratitude to Prof. Dr. Ahmed Abbas Raouf, Professor of Biochemistry and Dean of Liver Institute, Menoufiya University for his help and cooperation.

My sincere gratitude and my thanks to Dr. Heba Hassan El-Sedfy, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University for her help and advice.

I would like to express my deepest thanks to Dr. Ahmed El-Shaarawy, Lecturer of Clinical Pathology, Liver Institute, Menoufiya University for his help and support.

In addition, I would like to express my deepest thanks to Prof. Dr. Bahaa Hassanin, Professor of Pediatrics, Faculty of Medicine, Benha University and supervisor of Pediatrics Department, Liver Institute, Menoufiya University for his help and advice.

LIST OF TABLES

• **Tables of the review:**

Table (1):	Etiology of chronic hepatitis	5
Table (2):	Components of histological activity index (HAI)	9
Table (3):	Scoring system for staging of chronic hepatitis	10
Table (4):	Systemic disorders associated with AIH	18
Table (5):	Probable defects in the cellular immune response leading to establishment of chronic HBV infection	25
Table (6):	Events causing exacerbation of symptoms in patients with chronic HBV disease	27
Table (7):	Interferon-alpha in treatment of chronic HBV infection	28
Table (8):	Interferon-alpha in treatment of chronic HCV infection	36
Table (9):	Manifestations of Wilson's disease	41
Table (10):	Diagnosis of Wilson's disease	43
Table (11):	Diseases resulting in cirrhosis	53
Table (12):	Hepatic involvement in GSD	86
Table (13):	Components of self-tolerance	89
Table (14):	Possible factors perpetuating an immune response	90
Table (15):	Autoantibodies in autoimmune liver diseases	99
Table (16):	Subspecificities and disease associates of AMA	101

• **Tables in the results:**

Table (1):	Age of the studied groups	119
Table (2):	Gender of the studied groups	119
Table (3):	Clinical presentation of the studied groups	121
Table (4):	Comparison between number and percentage of different clinical presentation of autoimmune and non-autoimmune groups	122
Table (5):	Ultrasonographic findings of the studied groups	124
Table (6):	Ultrasonographic findings of the autoimmune and non-autoimmune groups	125
Table (7):	Liver function tests of the studied groups	126
Table (8):	Comparison of studied liver function tests between autoimmune and non-autoimmune groups	127
Table (9):	Comparison of studied liver function tests between autoimmune hepatitis group and the controls	128
Table (10):	Comparison of studied liver function tests between non-autoimmune group and controls	129
Table (11):	Liver biopsy of the studied groups	132
Table (12):	Comparison of liver biopsy between the autoimmune and non-autoimmune groups	133
Table (13):	Mean value and SD of γ -globulins, platelets, RBCs and WBCs in the studied groups	134
Table (14):	Comparison of the mean value of γ -globulins, platelet, RBC and WBC counts between autoimmune and non-autoimmune groups	137

Table (15): Comparison of the mean value of γ - globulins, platelet, RBC and WBC counts between autoimmune and control groups	138
Table (16): Comparison of the mean value of γ - globulin, platelet, RBC and WBC counts between non-autoimmune and control groups	139
Table (17): Number and percentage of positive autoantibody cases in autoimmune and non-autoimmune liver disease	140
Table (18): Hepatitis viral markers in the AIH group	140
Table (19): Number and percentage distribution of autoantibodies in different studied liver disease patients and controls	142
Table (20): Number and percentage distribution of autoantibodies in autoimmune, non-autoimmune and control groups	144
Table (21): Distribution of ANA titres in studied groups	146
Table (22): Distribution of AMA titres in studied groups	148
Table (23): Distribution of ASMA titres in studied groups	150
Table (24): Distribution of PCA titres in studied groups	152
Table (25): Distribution of LKM titres in studied groups	154
Table (26): Comparison of different ANA titres between autoimmune and non-autoimmune groups	156
Table (27): Comparison of different AMA titres between autoimmune and non-autoimmune groups	157
Table (28): Comparison of different ASMA titres between autoimmune and non-autoimmune groups	158

Table (29): Comparison of different PCA titres between autoimmune and non-autoimmune groups	159
Table (30): Comparison of different LKM titres between autoimmune and non-autoimmune groups	160
Table (31): Number and percentage distribution of type I and type II in the AIH group	161

LIST OF FIGURES

• **Figures in the review:**

- Fig. (1): Structure of the HCV genome and associated viral proteins 33
- Fig. (2): Metabolites in glycogen formation and glycolysis 82

• **Figures in the results:**

- Fig. (1): Gender distribution of the studied groups 120
- Fig. (2): Comparison between percentage of different clinical presentations of autoimmune and non-autoimmune group 123
- Fig. (3): Comparison of AST and ALT between AIH, non-autoimmune and control groups 130
- Fig. (4): Comparison of total and direct bilirubin, total proteins, albumin and prothrombin time between autoimmune, non-autoimmune and control groups 131
- Fig. (5): Mean value of γ -globulins in the studied groups 135
- Fig. (6): Mean value of platelet count in the studied groups 136
- Fig. (7): Percentage distribution of autoantibodies in autoimmune and non-autoimmune liver disease 141
- Fig. (8): The highest ANA titre in the different studied groups 147
-

Fig. (9):	The highest AMA titre in the different studied groups	149
Fig. (10):	The highest ASMA titre in the different studied groups	151
Fig. (11):	The highest PCA titre in the different studied groups	153
Fig. (12):	The highest LKM titre in the different studied groups	155
